Contineum Therapeutics, Inc. Class A Common Stock (CTNM NASDAQ) stock market data APIs
$10.8154
-0.14(-1.3%)
as of November 11, 2026
Try our APIs with
free plan!
Contineum Therapeutics, Inc. Class A Common Stock Financial Data Overview
Price chart is built with
Anychart
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Prev. Close
10.8154
Open
10.6757
High
10.9553
Low
10.479
52 wk Range
6.725-17.785
Market Cap
423 M
Shares Outstanding
35 353 K
EPS
-0.49
Beta
1.07
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Contineum Therapeutics, Inc. Class A Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Contineum Therapeutics, Inc. Class A Common Stock data using free add-ons & libraries
Get Contineum Therapeutics, Inc. Class A Common Stock Fundamental Data
Contineum Therapeutics, Inc. Class A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -72 030 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Contineum Therapeutics, Inc. Class A Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-03
- EPS/Forecast: -0.45
Get Contineum Therapeutics, Inc. Class A Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Contineum Therapeutics, Inc. Class A Common Stock News
New
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
SAN DIEGO, October 29, 2026--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecul...
BMY Reports Mixed Phase III Trial Results, Stock Down
Bristol Myers Squibb BMY announced mixed phase III results for admilparant, its investigational treatment for idiopathic pulmonary fibrosis (IPF). The company also reported positive results from the ...
Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028. Continue Reading
Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes
Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock fell, however. Continue Reading
Get Contineum Therapeutics, Inc. Class A Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.